On November 17, 2020, our company received the "Letter of Approval for the Listing of Beijing Northland Biotechnology Co., Ltd. on the Select Tier of the National SME Share Transfer System." Following review and approval by the National Equities Exchange and Quotations Company, the company's shares will be listed on the Select Tier of the National Equities Exchange and Quotations System on November 24, 2020, and the trading method will be changed to continuous auction.

　　Since the company officially launched its listing on the Select Tier in March of this year, and with the guidance and sponsorship of Zhongtai Securities, the company has smoothly completed the transition from the Basic Tier to the Innovation Tier and will officially move up to the Select Tier on the 24th. Throughout this process, the company has attracted considerable attention from a wide range of investment institutions and investors.

　　Listing on the Select Tier marks an important milestone in NORTHLAND's development. We will take our listing on the Select Tier as a brand-new starting point, fully commit ourselves to accelerating the R&D process of new drugs, and strive to bring our products to market at an early date. We aim to deliver outstanding performance to repay society, reward our shareholders, and live up to the trust and support we’ve received from leaders at all levels and friends from all walks of life. At the same time, we will steadfastly fulfill our obligations as a public company and act as a responsible enterprise, living up to the deep affection and high expectations that all investors have placed in NORTHLAND!